NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Monday morning,Benzinga reports. They currently have a $31.00 price target on the stock.

NRXP has been the topic of a number of other reports. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of NRx Pharmaceuticals in a research report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Stock Down 19.3 %

NASDAQ NRXP opened at $3.76 on Monday. The firm’s 50-day simple moving average is $1.58 and its two-hundred day simple moving average is $1.78. The company has a market cap of $45.47 million, a PE ratio of -1.76 and a beta of 1.08. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $7.33.

Insider Activity

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt bought 40,000 shares of the firm’s stock in a transaction on Tuesday, December 17th. The stock was acquired at an average price of $1.17 per share, with a total value of $46,800.00. Following the completion of the purchase, the chairman now owns 84,634 shares of the company’s stock, valued at approximately $99,021.78. This trade represents a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 19.00% of the stock is currently owned by company insiders.

Institutional Trading of NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP bought a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned about 1.33% of NRx Pharmaceuticals at the end of the most recent quarter. Institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.